Jan 21, 2015
Hepatitis C is a life-or-death disease of the liver that's known to be prevalent in third-world countries. But, with a steep medication price, treatment is often times a luxury. But with new Indian-based pharmaceutical companies joining Gilead, that all may change in the near future.
Jan 21, 2015
After months of waiting and anticipation, the hepatitis C treatment price wars are finally getting under way. Express Scripts, the largest pharmacy benefits manager in the U.S., has released a new treatment from AbbVie as its exclusive treatment for patients with genotype 1, the most common form of the chronic disease. This drug covers 75% of the estimated 3.2 million Americans who are infected. And this new drug will likely change the market for the hepatitis C treatments that are currently led by a pair of medications from Gilead Sciences which is likely to reach $20 billion in revenue next year thanks to demand for its treatments.
2. 08:31 AM
Chemical added to consumer products impairs response to antibiotic treatment
3. 08:16 AM
Correct antibiotic dosing could preserve lung microbial diversity in cystic fibrosis
4. 08:12 AM
Hubble helps uncover origin of Neptune's smallest moon Hippocamp